PROTAC MLKL Degrader-2

PROTAC MLKL Degrader-2

• UNSPSC Description: PROTAC MLKL Degrader-2 (compound MP-1) is a PROTAC targeting MLKL (Mixed Lineage Kinase). PROTAC MLKL Degrader-2 is composed of PROTAC target protein ligand PROTAC MLKL Degrader-2 (HY-169072) (red part), E3 ligase ligand Thalidomide (HY-14658) (blue part) and PROTAC Linker N-Methylpiperazine (HY-78871) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is Thalidomide-N-methylpiperazine (HY-169074)[1].
• Target Antigen: Mixed Lineage Kinase; PROTACs
• Type: Reference compound
• Related Pathways: MAPK/ERK Pathway;PROTAC
• Applications: Cancer-Kinase/protease
• Field of Research: cancer
• Assay Protocol: https://www.medchemexpress.com/protac-mlkl-degrader-2.html
• Smiles: O=C(NC1=CC=CC(C#CCN(C(N(C2=O)C)=O)C3=C2N(C(S(C)(=O)=O)=N3)C)=C1)CN4CCN(C5=CC6=C(C=C5)C(N(C6=O)C7CCC(NC7=O)=O)=O)CC4
• Molecular Weight: 769.78
• References & Citations: [1]Li S, et al. Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis. J Med Chem. 2024 Sep 12;67(17):15353-15372.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported